CLNN: Ascending Triangle detected on 19 Mar 2026
Overall Score
88
of 100
Strong
Win Probability
63%
Moderate
Reward / Risk
0.9
: 1
$0.10 reward
$-0.11 risk
Current Setup
CLNN forms an ascending triangle with strong post-collapse recovery pattern (34.0 pattern quality score), advancing 29 days from March 16 support structure. Price at $6.57 tests key resistance matching the immediate level, while structure score of 15.0/15 and breakout score of 13.0/13 signal a well-formed technical setup. Volume ratio of 1.35x above 20-day average (100,111 shares vs. 74,028 baseline) provides confluence. Overall score of 88 with 63.3% win probability indicates above-median pattern quality for systematic scanning. Support floor at $5.66 represents prior consolidation base. RSI at 70.93 signals momentum into overbought territory, meriting attention but not disqualifying.
Stock Context
Clene plans to file an accelerated CNM-Au8 ALS NDA in Q2 2026 and start a confirmatory Phase 3 RESTORE-ALS trial later this year. The company reported Q4 2025 earnings of ($0.88) EPS on March 12, missing consensus of ($0.74), with revenue of $0.08 million, creating near-term earnings disappointment despite clinical momentum. A $28 million registered direct offering in January 2026 provided $6.03M upfront and contingent tranches of $22M tied to NDA acceptance and FDA approval. Cash runway extends to Q3 2026 with potential financing into 2027. D. Boral Capital reiterated a buy rating with $23 price target, validating clinical pathway despite cash burn. CLNN has historically shown sharp but inconsistent stock responses to biomarker news and financing announcements.
What to Expect
Breakout above $6.57 resistance would target $6.97 conservatively based on ascending triangle measured move (6.0 point structure over support base). Pattern success requires volume expansion beyond current 1.35x ratio and sustained close above resistance to confirm structure integrity. Win probability of 63.3% aligns with post-collapse recovery patterns showing above-average probability of trend continuation after multi-week consolidation. Invalidation occurs on close below $5.66 support, which would signal pattern failure and potential retest of deeper support. Technical indicators suggest momentum already advanced; a measured 6.0% upside move would test near-term resistance without dramatic acceleration.
Risk Factors
Q4 2025 earnings miss of $0.14 EPS and continuing losses signal ongoing cash-burn concerns that could pressure valuation. Earnings report scheduled for March 23, 2026 falls immediately after the 19th detection date, introducing binary event risk. Prior S-3 resale capacity and dilution from warrant exercises tied to PDUFA and approval announcements create overhang. RSI at 70.93 exceeds 70 overbought threshold, flagging reversal risk after 55.69% one-month gain. Healthcare sector regime is bearish (-0.18 score); regulatory delays on Q1 2026 Type C FDA meeting could derail NDA timeline. Recent insider selling of 276,144 shares worth $1.47M contrasts with 35.30% insider ownership, signaling mixed conviction.
Sources:
Clene maps 2026 FDA milestones for CNM-Au8 NDA | CLNN Stock News
·
CLNN: Clene Inc - Stock Price, Quote and News - CNBC
·
CLNN - Clene Latest Stock News & Market Updates
·
Clene Inc. (CLNN) Stock Price, News, Quote & History - Yahoo Finance
·
Clene (CLNN) prices $28M registered direct offering above market | CLNN Stock News
·
Investor Relations | Clene Inc.
·
Clene Stock Price Forecast. Should You Buy CLNN?
·
Press Releases | Clene Inc.
·
Clene to Present Corporate Update on Jan. 21 | CLNN Stock News
·
Clene to present at Emerging Growth Conference Feb. 25 | CLNN Stock News
·
Clene’s (CLNN) “Buy” Rating Reiterated at D. Boral Capital - Markets Daily
·
CLNN: Clene Inc - Stock Price, Quote and News - CNBC
·
Clene Inc. (CLNN) Stock Price, News, Quote & History - Yahoo Finance
·
Clene Reports Full Year 2022 Financial Results and Recent Operating Highlights | Clene Inc.
·
What is HC Wainwright’s Forecast for Clene Q1 Earnings? - Daily Political
·
__symbol__ Stock Quote Price and Forecast | CNN
·
Clene Inc. Common Stock (CLNN) Earnings Report Dates & Earnings Forecasts | Nasdaq
·
Clene (CLNN) Stock Price, News & Analysis $CLNN
·
CLNN - Clene Latest Stock News & Market Updates
·
Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights
Market & Sector Regime
Market
Neutral
-0.19
-1.0
0
+1.0
Health Care Sector
Bearish
-0.18
-1.0
0
+1.0
Other Patterns Detected Today
Three White Soldiers
3 days in pattern
Moderate
27.7
Post Collapse Recovery
29 days in pattern
Strong
34.0
Overall Score
40
of 40
Pattern Quality
20
of 20
Setup
11
of 20
R/R
17
of 18
Context
Pattern Quality Score
15
of 15
Structure
13
of 13
Breakout
12
of 12
Volume
Recent Performance
Momentum & Trend
RSI (14)
70.9
Overbought
MACD Histogram
+0.12
Bullish
Bollinger Band Position
108.4%
Upper Band
Volatility & Risk
20-Day Volatility
0.71
Very High
ATR %
7.6%
High
Beta
0.82
Market
Volume Analysis
Volume Ratio
1.35x
Above Avg
20-Day Avg Vol
74K
shares / day
Current Volume
100K
shares traded
Price Levels
52W High
$13.50
Target
$6.97
Resistance
$6.57
Current
$6.57
Stop Loss
$5.97
Support
$5.66
52W Low
$2.28
Disclaimer: This analysis is algorithmically generated for educational purposes only and does not constitute financial advice. Past pattern performance does not guarantee future results. Win probabilities are based on historical data across 370,000+ observations. Always conduct your own research and consult a qualified financial advisor. AI-assisted contextual analysis by Claude (Anthropic). Indicators reflect values at time of detection.